TNF and fatty liver disease: Research involving obese murine models has demonstrated that the administration of oxidase inhibitors leads to increased adiponectin expression and decreased TNF-α expression, thereby mitigating complications such as diabetes, hyperlipidemia, and hepatic steatosis (32).